Home › Myelodysplastic Syndromes › Vermont › Burlington
Myelodysplastic Syndromes clinical trials in Burlington, VT
3 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Burlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
RecruitingObservational study
- University of Vermont Medical Center, Burlington
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
RecruitingObservational study
- University of Vermont, Burlington
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- Seattle, WA21 studies
- New York City, NY21 studies
- Washington, DC20 studies
- Boston, MA19 studies
- Tampa, FL19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Durham, NC14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
Other studies in Burlington
- Heart Failure8 studies
- Acute Myeloid Leukemia7 studies
- Cancer (all types)6 studies
- COPD5 studies
- Breast Cancer5 studies
- Parkinson's Disease4 studies
- Non-Small Cell Lung Cancer4 studies
- Prostate Cancer4 studies
- Cystic Fibrosis4 studies
- Lung Diseases4 studies
- Leukemia4 studies
- Cardiovascular Disease4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.